Capstone Capital Management Ltd Takes Position in Novo Nordisk A/S $NVO

Capstone Capital Management Ltd purchased a new position in Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 25,434 shares of the company’s stock, valued at approximately $935,000. Novo Nordisk A/S comprises about 0.9% of Capstone Capital Management Ltd’s investment portfolio, making the stock its 29th biggest holding.

Other hedge funds also recently bought and sold shares of the company. Quotient Wealth Partners LLC raised its holdings in Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after buying an additional 177 shares during the last quarter. Certuity LLC lifted its stake in shares of Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after buying an additional 177 shares in the last quarter. Oakworth Capital Inc. grew its holdings in shares of Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after buying an additional 182 shares during the last quarter. True North Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares during the last quarter. Finally, Asio Capital LLC increased its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock valued at $274,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.6%

NVO opened at $48.86 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average price of $45.23 and a 200-day moving average price of $45.84. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $71.79. The stock has a market capitalization of $218.17 billion, a price-to-earnings ratio of 11.47, a PEG ratio of 4.53 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. Equities research analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NVO. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective for the company. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Wolfe Research began coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday. Five analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk signed a pact with Vivani to explore a long-lasting semaglutide implant, which could broaden the company’s obesity and diabetes treatment pipeline beyond current oral and injectable products. Article Title
• Positive Sentiment: UBS reiterated a positive view on European pharmaceuticals, calling the sector a more resilient alternative to the AI trade; that broader support can help sentiment for Novo Nordisk as a leading European pharma name. Article Title
• Neutral Sentiment: MAHE and Novo Nordisk GBS expanded their collaboration in pharmacometrics, a constructive but likely limited near-term stock catalyst. Article Title
• Neutral Sentiment: Articles from July 7 highlighted a mixed debate on Novo Nordisk’s valuation and long-term outlook, with one bullish piece arguing the stock is still attractive and another downgrade saying the company may have lost some of its edge. Article Title Article Title
• Negative Sentiment: Deutsche Bank’s prescription tracker showed continued slowdown in the oral Wegovy pill in the U.S., reinforcing investor worries that growth in Novo Nordisk’s GLP-1 franchise may be decelerating. Article Title
• Negative Sentiment: Novo Nordisk also traded lower than the broader market in the latest session, reflecting ongoing weakness in the shares as investors digest the slower prescription trend. Article Title

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.